Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.49 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 2/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.46 |
| ▸ | GPR17 | Q13304 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19180617 | 0.99 | POLB (0.57) | POLBNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL2883759 | 0.91 | NT5E (0.58) | POLBNT5EENPP1P2RY1 | |
| SCHEMBL29642033 | 0.91 | NT5E (0.64) | POLBNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL15573313 | 0.91 | NT5E (0.64) | POLBNT5EP2RY6P2RY2P2RY4 | |
| SCHEMBL29465233 | 0.89 | POLB (0.65) | POLBP2RY2ENPP1P2RY1P2RX3 | |
| SCHEMBL1763078 | 0.89 | POLB (0.65) | POLBP2RY2ENPP1P2RY1P2RX3 | |
| SCHEMBL245486 | 0.89 | POLB (0.65) | POLBP2RY2ENPP1P2RY1P2RX3 | |
| SCHEMBL2508646 | 0.87 | POLB (0.66) | POLBNT5EP2RY2ENPP1P2RY1 | |
| SCHEMBL2508660 | 0.87 | POLB (0.66) | POLBNT5EP2RY2ENPP1P2RY1 | |
| Triphosphate SCHEMBL28101757 | 0.87 | POLB (0.61) | POLBNT5EP2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| JP-2011505845-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20110003700-A1 | ELIMINATION OF CONTAMINANTS ASSOCIATED WITH NUCLEIC ACID AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY LTD. (AU) | 2011-01-06 | — | — | US | claimed |
| EP-2222850-A1 | ELIMINATION OF CONTAMINANTS ASSOCIATED WITH NUCLEIC ACID AMPLIFICATION | Human Genetic Signatures Pty Ltd (AU) | 2010-09-01 | — | — | EP | claimed |
| WO-2009079703-A1 | ELIMINATION OF CONTAMINANTS ASSOCIATED WITH NUCLEIC ACID AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2009-07-02 | — | — | WO | claimed |
| EP-1595957-A1 | Phosphoglycerate mutases and enzyme products | Eigenbrodt, Erich (DE) | 2005-11-16 | — | — | EP | claimed |
| CN-122055456-A | Gene recognition profile for liver disease and uses thereof | 新加坡科技研究局 | 2026-05-15 | — | — | CN | disclosed |
| EP-4729632-A1 | METHOD OF SYNTHESIZING DNA | AskBio Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260028659-A1 | SYNTHESIS OF DNA WITH IMPROVED YIELD | Touchlight IP Limited (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4665865-A1 | METHODS OF MAKING DNA MOLECULES AND COMPOSITIONS AND USES THEREOF | Anjarium Biosciences AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025151077-A1 | A METHOD TO PREDICT AND TARGET RESISTANCE TO CHEMOTHERAPY IN A CANCER | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025133639-A1 | DUPLEXING METHOD | Touchlight IP Limited (GB) | 2025-06-26 | — | — | WO | disclosed |
| US-20250136636-A1 | NUCLEOTIDE COMPLEXES CAPABLE OF AN IMPROVED DNA SYNTHESIS YIELD | Touchlight IP Limited (GB) | 2025-05-01 | — | — | US | disclosed |
| US-7947477-B2 | Emulsion PCR and amplicon capture | APPLIED BIOSYSTEMS, LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110003700-A1 | ELIMINATION OF CONTAMINANTS ASSOCIATED WITH NUCLEIC ACID AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY LTD. (AU) | 2011-01-06 | — | — | US | disclosed |
| EP-2222850-A1 | ELIMINATION OF CONTAMINANTS ASSOCIATED WITH NUCLEIC ACID AMPLIFICATION | Human Genetic Signatures Pty Ltd (AU) | 2010-09-01 | — | — | EP | disclosed |
| US-20100129875-A1 | EMULSION PCR AND AMPLICON CAPTURE | Life Technologies Corporation (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2009079703-A1 | ELIMINATION OF CONTAMINANTS ASSOCIATED WITH NUCLEIC ACID AMPLIFICATION | HUMAN GENETIC SIGNATURES PTY LTD (AU) | 2009-07-02 | — | — | WO | disclosed |
| US-20080076909-A1 | EMULSION PCR AND AMPLICON CAPTURE | APPLERA CORPORATION (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008005675-A2 | EMULSION PCR AND AMPLICON CAPTURE | APPLERA CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028659-A1 | SYNTHESIS OF DNA WITH IMPROVED YIELD | POLB, DNMT3A, POLM | POLB 1/4885NT5E 163/4885P2RY6 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.